GSSD/
Articles/
2606004185
  • Open Access
  • Review

Pathways to Sustainable Biomanufacturing: Scalable Production of Biopharmaceutical Raw Materials and Biologics for Health Security

  • Richard M. Mariita 1,2,*,   
  • Jamie M. Reedy 3,4,   
  • Hyrine G. Munga 5,   
  • Britt Hafner 1

Received: 16 Jan 2026 | Revised: 20 May 2026 | Accepted: 08 Jun 2026 | Published: 15 Jun 2026

Abstract

The increasing global demand for biopharmaceutical biologics, including vaccines, monoclonal antibodies, enzymes, cytokines, hormones and growth factors, is driven by aging populations, rising cancer incidences, the persistent threat of pandemics such as COVID-19 and endemic infectious diseases such as Tuberculosis and Malaria. While the global biologics market is projected to surpass $1 trillion by 2034, current centralized manufacturing models rely heavily on resource-intensive mammalian systems that pose significant economic and logistical barriers, particularly for the Global South. This review evaluates the imperative for adopting sustainable biomanufacturing pathways to enhance global health security and sovereignty. We critically assess diverse production platforms, ranging from traditional microbial and mammalian cell lines to emerging green systems such as transgenic plants, algae, and cell-free synthesis, against the Triple Bottom Line framework: environmental stewardship, economic viability, and social responsibility. The analysis highlights that while mammalian cells remain the industry standard for complex post-translational modifications (PTMs), plant-based and cell-free platforms offer scalability, reduced carbon footprints, and the potential for decentralized production. Furthermore, the integration of artificial intelligence (AI), digital twins, and single-use technologies is identified as a catalyst for optimizing yield and facilitating net-zero emissions targets. For the Global South, these approaches offer opportunities to overcome resource limitations through localized, low-input platforms. We conclude that transitioning toward resilient, localized, and eco-friendly biomanufacturing is essential to mitigate supply chain vulnerabilities, ensure equitable access to life-saving therapeutics, and safeguard populations against future biological threats.

References 

  • 1.

    Rodin, G.; Feldman, A.; Trapani, D.; et al. The Human Crisis in Cancer: A Lancet Oncology Commission. Lancet Oncol. 2025, 26, e628–e670. https://doi.org/10.1016/S1470-2045(25)00530-3.

  • 2.

    Vollset, S.E.; Ababneh, H.S.; Abate, Y.H.; et al. Burden of Disease Scenarios for 204 Countries and Territories, 2022–2050: A Forecasting Analysis for the Global Burden of Disease Study 2021. Lancet 2024, 403, 2204–2256. https://doi.org/10.1016/S0140-6736(24)00685-8.

  • 3.

    Schumacher, A.E.; Zheng, P.; Barber, R.M.; et al. Global Age-Sex-Specific All-Cause Mortality and Life Expectancy Estimates for 204 Countries and Territories and 660 Subnational Locations, 1950–2023: A Demographic Analysis for the Global Burden of Disease Study 2023. Lancet 2025, 406, 1731–1810. https://doi.org/10.1016/S0140-6736(25)01330-3.

  • 4.

    Naghavi, M.; Kyu, H.H.; Aalipour, M.A.; et al. Global Burden of 292 Causes of Death in 204 Countries and Territories and 660 Subnational Locations, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023. Lancet 2025, 406, 1811–1872.

  • 5.

    Gianfredi, V.; Nucci, D.; Pennisi, F.; et al. Aging, Longevity, and Healthy Aging: The Public Health Approach. Aging Clin. Exp. Res. 2025, 37, 125. https://doi.org/10.1007/s40520-025-03021-8.

  • 6.

    Cummings, J.; Osse, A.M.L.; Cammann, D.; et al. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease. BioDrugs 2024, 38, 5–22. https://doi.org/10.1007/s40259-023-00633-2.

  • 7.

    Precedence Research Biologics Market Size to Exceed USD 1144.20 Billion by 2034 Amid Rising Demand for Monoclonal Antibodies, Vaccines, and Personalized Therapies. Available online: https://www.biospace.com/press-releases/biologics-market-size-to-exceed-usd-1-144-20-billion-by-2034-amid-rising-demand-for-monoclonal-antibodies-vaccines-and-personalized-therapies (accessed on 7 January 2026).

  • 8.

    Haydon, I. Biologics: The Pricey Drugs Transforming Medicine. Available online: https://www.scientificamerican.com/article/biologics-the-pricey-drugs-transforming-medicine/ (accessed on 7 January 2026).

  • 9.

    Lippi, G.; Sanchis-Gomar, F. Mortality of Post-COVID-19 Condition: 2025 Update. Covid 2025, 5, 11. https://doi.org/10.3390/covid5010011.

  • 10.

    Asin-Garcia, E.; Fawcett, J.D.; Batianis, C.; et al. A Snapshot of Biomanufacturing and the Need for Enabling Research Infrastructure. Trends Biotechnol. 2025, 43, 1000–1014. https://doi.org/10.1016/j.tibtech.2024.10.014.

  • 11.

    Mo, Y.; Wei, D.; Chen, X.; et al. The Burden of COVID-19 Death for Different Cancer Types: A Large Population-Based Study. J. Glob. Health 2025, 15, 04046. https://doi.org/10.7189/jogh.15.04046.

  • 12.

    Agha, M.; Agha, R. The Rising Prevalence of Obesity: Part A: Impact on Public Health. Int. J. Surg. Oncol. 2017, 2, e17. https://doi.org/10.1097/IJ9.0000000000000017.

  • 13.

    Ward, Z.J.; Bleich, S.N.; Cradock, A.L.; et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N. Engl. J. Med. 2019, 381, 2440–2450. https://doi.org/10.1056/NEJMsa1909301.

  • 14.

    Janssen, F.; Bardoutsos, A.; Vidra, N. Obesity Prevalence in the Long-Term Future in 18 European Countries and in the USA. Obes. Facts 2020, 13, 514–527. https://doi.org/10.1159/000511023.

  • 15.

    Greenwood, B.; Mutabingwa, T. Malaria in 2002. Nature 2002, 415, 670–672. https://doi.org/10.1038/415670a.

  • 16.

    Lu, R.-M.; Hwang, Y.-C.; Liu, I.-J.; et al. Development of Therapeutic Antibodies for the Treatment of Diseases. J. Biomed. Sci. 2020, 27, 1. https://doi.org/10.1186/s12929-019-0592-z.

  • 17.

    Walsh, G. Biopharmaceutical Benchmarks 2018. Nat. Biotechnol. 2018, 36, 1136–1145. https://doi.org/10.1038/nbt.4305.

  • 18.

    SNS Insider Human Growth Hormone Market to Hit USD 18.25 Billion by 2032, Driven by Expanding Therapeutic Applications and Biotech Advances SNS Insider. Available online: https://finance.yahoo.com/news/human-growth-hormone-market-hit-140000306.html (accessed on 7 January 2026).

  • 19.

    Tandon, S.; Sharma, A.; Singh, S.; et al. Therapeutic Enzymes: Discoveries, Production and Applications. J. Drug Deliv. Sci. Technol. 2021, 63, 102455. https://doi.org/10.1016/j.jddst.2021.102455.

  • 20.

    Lambert, J.M.; Chari, R.V.J. Ado-Trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer. J. Med. Chem. 2014, 57, 6949–6964. https://doi.org/10.1021/jm500766w.

  • 21.

    Przepiorka, D.; Ko, C.-W.; Deisseroth, A.; et al. FDA Approval: Blinatumomab. Clin. Cancer Res. 2015, 21, 4035–4039. https://doi.org/10.1158/1078-0432.CCR-15-0612.

  • 22.

    Martin, T.; Usmani, S.Z.; Berdeja, J.G.; et al. Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J. Clin. Oncol. 2023, 41, 1265–1274. https://doi.org/10.1200/JCO.22.00842.

  • 23.

    Flint, A.; Arslanian, S. Treatment of Type 2 Diabetes in Youth. Diabetes Care 2011, 34, S177–S183. https://doi.org/10.2337/dc11-s215.

  • 24.

    Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021, 384, 989–1002. https://doi.org/10.1056/NEJMoa2032183.

  • 25.

    Cox, T.M. Gaucher Disease: Clinical Profile and Therapeutic Developments. Biologics 2010, 4, 299–313. https://doi.org/10.2147/BTT.S7582.

  • 26.

    Zhao, Q.; Li, R.; Shao, Q.; et al. Recombinant Growth Hormone Improves Growth and Adult Height: A Comparison between Treated and Untreated Patients with Idiopathic Growth Hormone Deficiency. Transl. Pediatr. 2025, 14, 442–451. https://doi.org/10.21037/tp-2024-576.

  • 27.

    Bengtsson, B.A.; Edén, S.; Lönn, L.; et al. Treatment of Adults with Growth Hormone (GH) Deficiency with Recombinant Human GH. J. Clin. Endocrinol. Metab. 1993, 76, 309–317. https://doi.org/10.1210/jcem.76.2.8432773.

  • 28.

    Weinreich, D.M.; Sivapalasingam, S.; Norton, T.; et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N. Engl. J. Med. 2021, 385, e81. https://doi.org/10.1056/NEJMoa2108163.

  • 29.

    Abani, O.; Abbas, A.; Abbas, F.; et al. Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial. Lancet 2022, 399, 665–676. https://doi.org/10.1016/S0140-6736(22)00163-5.

  • 30.

    Gottlieb, R.L.; Nirula, A.; Chen, P.; et al. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2021, 325, 632–644. https://doi.org/10.1001/jama.2021.0202.

  • 31.

    Markham, A. REGN-EB3: First Approval. Drugs 2021, 81, 175–178. https://doi.org/10.1007/s40265-020-01452-3.

  • 32.

    Mulangu, S.; Dodd, L.E.; Davey, R.T., Jr.; et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N. Engl. J. Med. 2019, 381, 2293–2303. https://doi.org/10.1056/NEJMoa1910993.

  • 33.

    FDA; CDER; FDA. Approves Treatment for Ebola Virus. 2021. Available online: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-ebola-virus (accessed on 10 April 2026).

  • 34.

    Sapparapu, G.; Fernandez, E.; Kose, N.; et al. Neutralizing Human Antibodies Prevent Zika Virus Replication and Fetal Disease in Mice. Nature 2016, 540, 443–447. https://doi.org/10.1038/nature20564.

  • 35.

    Nkolola, J.P.; Hope, D.; Guan, R.; et al. Protective Threshold of a Potent Neutralizing Zika Virus Monoclonal Antibody in Rhesus Macaques. J. Virol. 2024, 98, e01429-24. https://doi.org/10.1128/jvi.01429-24.

  • 36.

    Lyke, K.E.; Berry, A.A.; Laurens, M.B.; et al. Human Monoclonal Antibody MAM01 for Protection against Malaria in Adults in the USA: A First-in-Human, Phase 1, Dose-Escalation, Double-Blind, Placebo-Controlled, Adaptive Trial. Lancet Infect. Dis. 2026, 26, 170–181. https://doi.org/10.1016/S1473-3099(25)00481-5.

  • 37.

    Skinner, J.; Kayentao, K.; Ongoiba, A.; et al. Anti-Sporozoite Monoclonal Antibody for Malaria Prevention: Secondary Efficacy Outcome of a Phase 2 Randomized Trial. Nat. Med. 2025, 31, 2682–2690. https://doi.org/10.1038/s41591-025-03739-y.

  • 38.

    Kayentao, K.; Ongoiba, A.; Preston, A.C.; et al. Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria. N. Engl. J. Med. 2024, 390, 1549–1559. https://doi.org/10.1056/NEJMoa2312775.

  • 39.

    World Health Organization. World Health Organization Staff. Global Tuberculosis Report; World Health Organization: Geneva, Switzerland, 2013; ISBN 92-4-156465-2.

  • 40.

    Tian, N.; Chu, H.; Li, Q.; et al. Host-Directed Therapy for Tuberculosis. Eur. J. Med. Res. 2025, 30, 267. https://doi.org/10.1186/s40001-025-02443-4.

  • 41.

    Zumla, A.; Rao, M.; Wallis, R.S.; et al. Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects. Lancet Infect. Dis. 2016, 16, e47–e63. https://doi.org/10.1016/S1473-3099(16)00078-5.

  • 42.

    Wallis, R.S.; Hafner, R. Advancing Host-Directed Therapy for Tuberculosis. Nat. Rev. Immunol. 2015, 15, 255–263. https://doi.org/10.1038/nri3813.

  • 43.

    Condos, R.; Rom, W.N.; Schluger, N.W. Treatment of Multidrug-Resistant Pulmonary Tuberculosis with Interferon-γ via Aerosol. Lancet 1997, 349, 1513–1515. https://doi.org/10.1016/S0140-6736(96)12273-X.

  • 44.

    Howat, P.; Stoneham, M. Why Sustainable Population Growth Is a Key to Climate Change and Public Health Equity. Health Promot. J. Aust. 2011, 22, S34–S38. https://doi.org/10.1071/he11434.

  • 45.

    Yao, T.; Asayama, Y. Animal-Cell Culture Media: History, Characteristics, and Current Issues. Reprod. Med. Biol. 2017, 16, 99–117. https://doi.org/10.1002/rmb2.12024.

  • 46.

    Walsh, G.; Walsh, E. Biopharmaceutical Benchmarks 2022. Nat. Biotechnol. 2022, 40, 1722–1760. https://doi.org/10.1038/s41587-022-01582-x.

  • 47.

    Marshall, D.; O’Dochartaigh, A.; Prothero, A.; et al. Are You Ready for the Sustainable, Biocircular Economy? Bus. Horiz. 2023, 66, 805–816. https://doi.org/10.1016/j.bushor.2023.05.002.

  • 48.

    Kadolkar, R.; Kumar, V.; Thole, A.; et al. Distributed Biomanufacturing Facilities of the Future. Biotechnol. Bioeng. 2025, 122, 3249–3265. https://doi.org/10.1002/bit.70039.

  • 49.

    Horner, R. Pharmaceuticals and the Global South: A Healthy Challenge for Development Theory? Geogr. Compass 2016, 10, 363–377. https://doi.org/10.1111/gec3.12277.

  • 50.

    Jakovljevic, M.; Liu, Y.; Cerda, A.; et al. The Global South Political Economy of Health Financing and Spending Landscape–History and Presence. J. Med. Econ. 2021, 24, 25–33. https://doi.org/10.1080/13696998.2021.2007691.

  • 51.

    Kis, Z.; Tak, K.; Ibrahim, D.; et al. Pandemic-Response Adenoviral Vector and RNA Vaccine Manufacturing. NPJ Vaccines 2022, 7, 29. https://doi.org/10.1038/s41541-022-00447-3.

  • 52.

    Crowell, L.E.; Lu, A.E.; Love, K.R.; et al. On-Demand Manufacturing of Clinical-Quality Biopharmaceuticals. Nat. Biotechnol. 2018, 36, 988–995. https://doi.org/10.1038/nbt.4262.

  • 53.

    Cao, L.; Zhang, Z.; Yuan, D.; et al. Tissue Engineering Applications of Recombinant Human Collagen: A Review of Recent Progress. Front. Bioeng. Biotechnol. 2024, 12, 1358246. https://doi.org/10.3389/fbioe.2024.1358246.

  • 54.

    Chen, Y.; Zhao, Y.; Zhang, X.; et al. Recombinant Human Collagen Type III Microgel: An Advanced Injectable Dermal Filler for Rejuvenating Aging Skin. Regen. Biomater. 2025, 12, rbaf076. https://doi.org/10.1093/rb/rbaf076.

  • 55.

    Liu, T.; Hao, J.; Lei, H.; et al. Recombinant Collagen for the Repair of Skin Wounds and Photo-Aging Damage. Regen. Biomater. 2024, 11, rbae108. https://doi.org/10.1093/rb/rbae108.

  • 56.

    Abdullahi, Y.B.; Ahmed, N.I.; Bashir, S.G.; et al. Empowering Health Sovereignty in Africa through Innovations for Self-Reliant Healthcare. Discov. Public Health 2025, 22, 770. https://doi.org/10.1186/s12982-025-01184-3.

  • 57.

    Kis, Z.; Kontoravdi, C.; Shattock, R.; et al. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines 2020, 9, 3. https://doi.org/10.3390/vaccines9010003.

  • 58.

    WHO Pandemic Prevention. Preparedness and Response Agreement. Available online: https://www.who.int/news-room/questions-and-answers/item/pandemic-prevention--preparedness-and-response-accord (accessed on 29 December 2025).

  • 59.

    Bulut, T.; Top, M.; Atan, M.; et al. Comparison of the Bulut Index-Beta Method and Global Health Security Index: Results from the World’s Countries. Turk. J. Med. Sci. 2024, 54, 822–837. https://doi.org/10.55730/1300-0144.5854.

  • 60.

    Gostin, L.O.; Katz, R. The International Health Regulations: The Governing Framework for Global Health Security. Milbank Q. 2016, 94, 264–313. https://doi.org/10.1111/1468-0009.12186.

  • 61.

    Sarkis, M.; Fyfe, A.T.; Kontoravdi, C.; et al. Towards a Net Zero, Socially Sustainable and Eco-Efficient Biopharma Industry: How Far Are We? Curr. Opin. Chem. Eng. 2024, 44, 101027. https://doi.org/10.1016/j.coche.2024.101027.

  • 62.

    Sodhi, V.; Singh, C.; Pal Singh Cheema, P.; et al. Simultaneous Sludge Minimization, Pollutant and Nitrogen Removal Using Integrated MBBR Configuration for Tannery Wastewater Treatment. Bioresour. Technol. 2021, 341, 125748. https://doi.org/10.1016/j.biortech.2021.125748.

  • 63.

    Attal-Juncqua, A.; Getz, J.; Morhard, R.; et al. Integrating Safety, Security, Sustainability, and Social Responsibility Principles into the U.S. Bioeconomy. mSphere 2024, 9, e00084-24. https://doi.org/10.1128/msphere.00084-24.

  • 64.

    Kanakia, A.; Sale, M.; Zhao, L.; et al. AI In Action: Redefining Drug Discovery and Development. Clin. Transl. Sci. 2025, 18, e70149. https://doi.org/10.1111/cts.70149.

  • 65.

    Boutagayout, A.; Ezzouggari, R.; Kouighat, M.; et al. Chapter 1-Advances in Artificial Intelligence for Plant Biology and Crop Breeding: An Overview. In AI Technologies for Crop Breeding; Chen, J.-T., Ed.; Academic Press: Cambridge, MA, USA, 2026; pp. 1–33. ISBN 978-0-443-33633-1.

  • 66.

    AGC Biologics. AGC Biologics Completes Copenhagen Campus Expansion Biomanufacturing. Available online: https://www.agcbio.com/news/agc-biologics-completes-copenhagen-campus-expansion (accessed on 30 December 2025).

  • 67.

    Sondell, M.; Andersson, N.; Nilsson, B. Automatic Generation of a Digital Twin for Continuous Antibody Capture. J. Chromatogr. A 2026, 1766, 466611. https://doi.org/10.1016/j.chroma.2025.466611.

  • 68.

    Tinkoff, D.; Zurkiya, D.; Leydon, E.; et al. Reimagining Life Science Enterprises with Agentic AI. 2025. Available online: https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-life-science-enterprises-with-agentic-ai#/ (accessed on 10 April 2026).

  • 69.

    David Gómez-Rios, H.R.-M. Towards Bioprocessing 4.0: Scaling Sustainable Innovation in the Pharmaceutical Bioeconomy. J. Appl. Pharm. Sci. 2025, 15, 001–003.

  • 70.

    Chung, Y.H.; Church, D.; Koellhoffer, E.C.; et al. Integrating Plant Molecular Farming and Materials Research for Next-Generation Vaccines. Nat. Rev. Mater. 2022, 7, 372–388. https://doi.org/10.1038/s41578-021-00399-5.

  • 71.

    Sung, H.; Ferlay, J.; Siegel, R.L.; et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. https://doi.org/10.3322/caac.21660.

  • 72.

    Gashema, P.; Musafiri, T.; Ndahimana, F.; et al. Mpox in East Africa: Learning from COVID-19 and Ebola to Strengthen Public Health Responses. Viruses 2024, 16, 1578. https://doi.org/10.3390/v16101578.

  • 73.

    MarketsandMarkets. Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032. Available online: https://natlawreview.com/press-releases/global-gene-therapy-market-surge-usd-3655-billion-2032-marketsandmarketstm (accessed on 30 December 2025).

  • 74.

    von der Leyen, H.; Delgado, J.; Mazouz, C.; et al. Implementation of a Quality Management System for Decentralized Manufacturing of Cell and Gene Therapy Products-Technical and Regulatory Considerations. Front. Med. 2025, 12, 1591751. https://doi.org/10.3389/fmed.2025.1591751.

  • 75.

    Oluyemi, G.F.; Afolabi, R.O.; Zamora, S.C.; et al. Environmental Impact Assessment of a Plant Cell-Based Bio-Manufacturing Process for Producing Plant Natural Product Ingredients. Sustainability 2024, 16, 8515. https://doi.org/10.3390/su16198515.

  • 76.

    Nicholson, A.; Negussie, Y.; Shah, C.M.; et al. The Convergence of Infectious Diseases and Noncommunicable Diseases: Proceedings of a Workshop. In The Convergence of Infectious Diseases and Noncommunicable Diseases: Proceedings of a Workshop; National Academies Press (US): Washington, DC, USA, 2019.

  • 77.

    Hacker, K. The Burden of Chronic Disease. Mayo Clin. Proc. Innov. Qual. Outcomes 2024, 8, 112–119. https://doi.org/10.1016/j.mayocpiqo.2023.08.005.

  • 78.

    CDC Fast Facts: Health and Economic Costs of Chronic Conditions. Available online: https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html (accessed on 12 January 2026).

  • 79.

    Leach-Kemon, K.; Loeffler, M.; Islam, M. Global Burden of Disease 2023: Findings from the GBD 2023 Study | Institute for Health Metrics and Evaluation. Available online: https://www.healthdata.org/research-analysis/library/global-burden-disease-2023-findings-gbd-2023-study (accessed on 12 January 2026).

  • 80.

    Liu, Q.; Liu, M.; Liang, W.; et al. Global Distribution and Health Impact of Infectious Disease Outbreaks, 1996–2023: A Worldwide Retrospective Analysis of World Health Organization Emergency Event Reports. J. Glob Health 2025, 15, 04151. https://doi.org/10.7189/jogh.15.04151.

  • 81.

    Samsudin, E.Z.; Yasin, S.M.; Ruslan, N.-H.; et al. Socioeconomic Impacts of Airborne and Droplet-Borne Infectious Diseases on Industries: A Systematic Review. BMC Infect. Dis. 2024, 24, 93. https://doi.org/10.1186/s12879-024-08993-y.

  • 82.

    Zhu, Y.-G.; Gillings, M.; Penuelas, J. Integrating Biomedical, Ecological, and Sustainability Sciences to Manage Emerging Infectious Diseases. One Earth 2020, 3, 23–26. https://doi.org/10.1016/j.oneear.2020.06.004.

  • 83.

    Biosimilars: Expanding Access to Essential Biologic Therapies. Available online: https://www.who.int/news/item/13-02-2025-biosimilars--expanding-access-to-essential-biologic-therapies (accessed on 12 January 2026).

  • 84.

    Puccetti, M.; Pariano, M.; Schoubben, A.; et al. Biologics, Theranostics, and Personalized Medicine in Drug Delivery Systems. Pharmacol. Res. 2024, 201, 107086. https://doi.org/10.1016/j.phrs.2024.107086.

  • 85.

    Durán-Lobato, M.; Niu, Z.; Alonso, M.J. Oral Delivery of Biologics for Precision Medicine. Adv. Mater. 2020, 32, 1901935. https://doi.org/10.1002/adma.201901935.

  • 86.

    Lee, N.K.; Chang, J.W. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation. Ann. Lab. Med. 2024, 44, 314–323. https://doi.org/10.3343/alm.2023.0382.

  • 87.

    Douglas, M.J.; Green, L.; Timmis, J.; et al. How Can ‘Health in All Policies’ Help Maximise the Potential of Microbial Biotechnologies for Health, Equity and Sustainability? Microb. Biotechnol. 2025, 18, e70194. https://doi.org/10.1111/1751-7915.70194.

  • 88.

    Kitney, R.I.; Bell, J.; Philp, J. Build a Sustainable Vaccines Industry with Synthetic Biology. Trends Biotechnol. 2021, 39, 866–874. https://doi.org/10.1016/j.tibtech.2020.12.006.

  • 89.

    BARDA. Medical Countermeasures | USA Public Health Security. Available online: https://medicalcountermeasures.gov/ (accessed on 12 January 2026).

  • 90.

    Facini, A. A Biomanufacturing Plan to Confront Future Biological Threats-The Council on Strategic Risks. Available online: https://councilonstrategicrisks.org/2024/09/04/a-biomanufacturing-plan-to-confront-future-biological-threats/ (accessed on 12 January 2026).

  • 91.

    FDA. About Advanced Manufacturing for Public Health Emergency Preparedness and Response; FDA: Silver Spring, MD, USA, 2023.

  • 92.

    Etit, D.; Meramo, S.; Ögmundarson, Ó.; et al. Can Biotechnology Lead the Way toward a Sustainable Pharmaceutical Industry? Curr. Opin. Biotechnol. 2024, 87, 103100. https://doi.org/10.1016/j.copbio.2024.103100.

  • 93.

    Labant, M.A. Biomanufacturing’s Green Theme: Sustainability Is a Challenge for the Biopharma Industry, Which Is Highly Regulated and Burdened with Legacy Facilities. Genet. Eng. Biotechnol. News 2024, 44, 36–40. https://doi.org/10.1089/gen.44.02.13.

  • 94.

    Farlow, A.; Torreele, E.; Gray, G.; et al. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs. Vaccines 2023, 11, 690. https://doi.org/10.3390/vaccines11030690.

  • 95.

    Green, L.; Ashton, K.; Bellis, M.A.; et al. ‘Health in All Policies’—A Key Driver for Health and Well-Being in a Post-COVID-19 Pandemic World. Int. J. Environ. Res. Public Health 2021, 18, 9468. https://doi.org/10.3390/ijerph18189468.

  • 96.

    Fenner, C.; Grilo, A.L.; James, I.; et al. The Journey towards mRNA Vaccine Technology Transfer: From Knowledge to Implementation. Vaccine X 2026, 29, 100787. https://doi.org/10.1016/j.jvacx.2026.100787.

  • 97.

    Haakuria, V.M.; Munezero, P.C.; Valdes, R.; et al. Building Vaccine and Biotherapeutics Manufacturing Capacity in Africa: A Practical Approach. Discov. Med. 2025, 2, 108. https://doi.org/10.1007/s44337-025-00313-w.

  • 98.

    Ntais, C.; Kontodimopoulos, N.; Fanourgiakis, J.; et al. Fostering Healthcare System Sustainability through Efficient Practices: Can Adopting Biosimilars Ease the Financial Burden of Rheumatoid Arthritis? F1000Research 2025, 13, 1128. https://doi.org/10.12688/f1000research.156983.2.

  • 99.

    Overton, T.W. Recombinant Protein Production in Bacterial Hosts. Drug Discov. Today 2014, 19, 590–601. https://doi.org/10.1016/j.drudis.2013.11.008.

  • 100.

    Rosano, G.L.; Ceccarelli, E.A. Recombinant Protein Expression in Escherichia Coli: Advances and Challenges. Front. Microbiol. 2014, 5, 172. https://doi.org/10.3389/fmicb.2014.00172.

  • 101.

    Baeshen, N.A.; Baeshen, M.N.; Sheikh, A.; et al. Cell Factories for Insulin Production. Microb. Cell Fact. 2014, 13, 141. https://doi.org/10.1186/s12934-014-0141-0.

  • 102.

    Liu, C.-P.; Tsai, T.-I.; Cheng, T.; et al. Glycoengineering of Antibody (Herceptin) through Yeast Expression and in Vitro Enzymatic Glycosylation. Proc. Natl. Acad. Sci. USA 2018, 115, 720–725. https://doi.org/10.1073/pnas.1718172115.

  • 103.

    Nooraei, S.; Bahrulolum, H.; Hoseini, Z.S.; et al. Virus-like Particles: Preparation, Immunogenicity and Their Roles as Nanovaccines and Drug Nanocarriers. J. Nanobiotechnol 2021, 19, 59. https://doi.org/10.1186/s12951-021-00806-7.

  • 104.

    Wang, G.; Huang, M.; Nielsen, J. Exploring the Potential of Saccharomyces Cerevisiae for Biopharmaceutical Protein Production. Curr. Opin. Biotechnol. 2017, 48, 77–84. https://doi.org/10.1016/j.copbio.2017.03.017.

  • 105.

    Nylen, A.; Chen, M.-T. Production of Full-Length Antibody by Pichia Pastoris. Methods Mol. Biol. 2018, 1674, 37–48. https://doi.org/10.1007/978-1-4939-7312-5_3.

  • 106.

    Buckland, B.; Sanyal, G.; Ranheim, T.; et al. Vaccine Process Technology—A Decade of Progress. Biotechnol. Bioeng. 2024, 121, 2604–2635. https://doi.org/10.1002/bit.28703.

  • 107.

    Mattanovich, D.; Branduardi, P.; Dato, L.; et al. Recombinant Protein Production in Yeasts. Methods Mol. Biol. 2012, 824, 329–358. https://doi.org/10.1007/978-1-61779-433-9_17.

  • 108.

    Chakrabarti, L.; Mathew, A.; Li, L.; et al. Mitochondrial Membrane Potential Identifies Cells with High Recombinant Protein Productivity. J. Immunol. Methods 2019, 464, 31–39. https://doi.org/10.1016/j.jim.2018.10.007.

  • 109.

    Handlogten, M.W.; Bosley, S.; Dunn, S.; et al. Accelerated Cell Culture Process Development and Characterization for Cilgavimab/Tixagevimab (AZD7442) for the Prevention and Treatment of COVID-19. Biotechnol. Bioeng. 2025, 122, 2308–2318. https://doi.org/10.1002/bit.28336.

  • 110.

    Young, A.; Isaacs, A.; Scott, C.A.P.; et al. A Platform Technology for Generating Subunit Vaccines against Diverse Viral Pathogens. Front. Immunol. 2022, 13, 963023. https://doi.org/10.3389/fimmu.2022.963023.

  • 111.

    Dumont, J.; Euwart, D.; Mei, B.; et al. Human Cell Lines for Biopharmaceutical Manufacturing: History, Status, and Future Perspectives. Crit. Rev. Biotechnol. 2016, 36, 1110–1122. https://doi.org/10.3109/07388551.2015.1084266.

  • 112.

    Cox, M.M.J.; Hollister, J.R. FluBlok, a next Generation Influenza Vaccine Manufactured in Insect Cells. Biologicals 2009, 37, 182–189. https://doi.org/10.1016/j.biologicals.2009.02.014.

  • 113.

    Felberbaum, R.S. The Baculovirus Expression Vector System: A Commercial Manufacturing Platform for Viral Vaccines and Gene Therapy Vectors. Biotechnol. J. 2015, 10, 702–714. https://doi.org/10.1002/biot.201400438.

  • 114.

    Kovaleva, E.S.; O’Connell, K.P.; Buckley, P.; et al. Recombinant Protein Production in Insect Larvae: Host Choice, Tissue Distribution, and Heterologous Gene Instability. Biotechnol. Lett. 2009, 31, 381–386. https://doi.org/10.1007/s10529-008-9883-2.

  • 115.

    Manini, I.; Trombetta, C.M.; Lazzeri, G.; et al. Egg-Independent Influenza Vaccines and Vaccine Candidates. Vaccines 2017, 5, 18. https://doi.org/10.3390/vaccines5030018.

  • 116.

    Perdue, M.L.; Swayne, D.E. Public Health Risk from Avian Influenza Viruses. Avian Dis. 2005, 49, 317–327. https://doi.org/10.1637/7390-060305R.1.

  • 117.

    Zahmanova, G.; Aljabali, A.A.A.; Takova, K.; et al. Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals. Int. J. Mol. Sci. 2023, 24, 17575. https://doi.org/10.3390/ijms242417575.

  • 118.

    In Brief: Taliglucerase (Elelyso) for Gaucher Disease; The Medical Letter Inc.: New Rochelle, NY, USA, 2012.

  • 119.

    Vo, D.-K.; Trinh, K.T. Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines. Vaccines 2025, 13, 191. https://doi.org/10.3390/vaccines13020191.

  • 120.

    Shi, Y.; Jiao, Q.; Hu, X.; et al. Recent Advances in Plant-Based Vaccines: From Molecular Farming Innovations to Global Health Applications. Biotechnol. J. 2025, 20, e70120. https://doi.org/10.1002/biot.70120.

  • 121.

    He, Y.; Ning, T.; Xie, T.; et al. Large-Scale Production of Functional Human Serum Albumin from Transgenic Rice Seeds. Proc. Natl. Acad. Sci. USA 2011, 108, 19078–19083. https://doi.org/10.1073/pnas.1109736108.

  • 122.

    Yang, L.; Hirose, S.; Takahashi, H.; et al. Recombinant Protein Yield in Rice Seed Is Enhanced by Specific Suppression of Endogenous Seed Proteins at the Same Deposit Site. Plant Biotechnol. J. 2012, 10, 1035–1045. https://doi.org/10.1111/j.1467-7652.2012.00731.x.

  • 123.

    Tschofen, M.; Knopp, D.; Hood, E.; et al. Plant Molecular Farming: Much More than Medicines. Annu. Rev. Anal. Chem. 2016, 9, 271–294.

  • 124.

    Dondapati, S.K.; Stech, M.; Zemella, A.; et al. Cell-Free Protein Synthesis: A Promising Option for Future Drug Development. BioDrugs 2020, 34, 327–348. https://doi.org/10.1007/s40259-020-00417-y

  • 125.

    Wang, K.Y.; Guo, Y. Editorial: Plant Molecular Farming for Biopharmaceutical Production and Beyond. Front. Plant Sci. 2026, 16, 1765245. https://doi.org/10.3389/fpls.2025.1765245.

  • 126.

    Buyel, J.F. Process Development Strategies in Plant Molecular Farming. Curr. Pharm. Biotechnol. 2015, 16, 966–982. https://doi.org/10.2174/138920101611150902115413.

  • 127.

    Sabalza, M.; Vamvaka, E.; Christou, P.; et al. Seeds as a Production System for Molecular Pharming Applications: Status and Prospects. Curr. Pharm. Des. 2013, 19, 5543–5552. https://doi.org/10.2174/1381612811319310009.

  • 128.

    Rosa, S.S.; Prazeres, D.M.F.; Azevedo, A.M.; et al. mRNA Vaccines Manufacturing: Challenges and Bottlenecks. Vaccine 2021, 39, 2190–2200. https://doi.org/10.1016/j.vaccine.2021.03.038.

  • 129.

    Claassens, N.J.; Burgener, S.; Vögeli, B.; et al. A Critical Comparison of Cellular and Cell-Free Bioproduction Systems. Curr. Opin. Biotechnol. 2019, 60, 221–229. https://doi.org/10.1016/j.copbio.2019.05.003.

  • 130.

    Banerjee, A.; Ward, V. Production of Recombinant and Therapeutic Proteins in Microalgae. Curr. Opin. Biotechnol. 2022, 78, 102784. https://doi.org/10.1016/j.copbio.2022.102784.

  • 131.

    Rasala, B.A.; Mayfield, S.P. Photosynthetic Biomanufacturing in Green Algae; Production of Recombinant Proteins for Industrial, Nutritional, and Medical Uses. Photosynth. Res. 2015, 123, 227–239. https://doi.org/10.1007/s11120-014-9994-7.

  • 132.

    Reski, R.; Parsons, J.; Decker, E.L. Moss-made Pharmaceuticals: From Bench to Bedside. Plant Biotechnol. J. 2015, 13, 1191–1198. https://doi.org/10.1111/pbi.12401.

  • 133.

    Dehghani, J.; Adibkia, K.; Movafeghi, A.; et al. Towards a New Avenue for Producing Therapeutic Proteins: Microalgae as a Tempting Green Biofactory. Biotechnol. Adv. 2020, 40, 107499. https://doi.org/10.1016/j.biotechadv.2019.107499.

  • 134.

    Rasala, B.A.; Muto, M.; Lee, P.A.; et al. Production of Therapeutic Proteins in Algae, Analysis of Expression of Seven Human Proteins in the Chloroplast of Chlamydomonas Reinhardtii. Plant Biotechnol. J. 2010, 8, 719–733. https://doi.org/10.1111/j.1467-7652.2010.00503.x.

  • 135.

    Rosales-Mendoza, S. Algae-Based Biopharmaceuticals; Springer International Publishing AG: Cham, Switzerland, 2016; ISBN 978-3-319-32230-8.

  • 136.

    Berndt, A.J.; Smalley, T.N.; Ren, B.; et al. Recombinant Production of a Functional SARS-CoV-2 Spike Receptor Binding Domain in the Green Algae Chlamydomonas Reinhardtii. PLoS ONE 2021, 16, e0257089. https://doi.org/10.1371/journal.pone.0257089.

  • 137.

    Schuster, M.; Jost, W.; Mudde, G.C.; et al. In Vivo Glyco-engineered Antibody with Improved Lytic Potential Produced by an Innovative Non-mammalian Expression System. Biotechnol. J. 2007, 2, 700–708. https://doi.org/10.1002/biot.200600255.

  • 138.

    Kircheis, R.; Halanek, N.; Koller, I.; et al. Correlation of ADCC Activity with Cytokine Release Induced by the Stably Expressed, Glyco-Engineered Humanized Lewis Y-Specific Monoclonal Antibody MB314. mAbs 2012, 4, 532–541. https://doi.org/10.4161/mabs.20577.

Share this article:
Download PDF
DOI
10.53941/gssd.2026.100019
Issue
Volume 1, Issue 1
How to Cite
Mariita, R. M.; Reedy, J. M.; Munga, H. G.; Hafner, B. Pathways to Sustainable Biomanufacturing: Scalable Production of Biopharmaceutical Raw Materials and Biologics for Health Security. Global South & Sustainable Development 2026, 1 (1), 19. https://doi.org/10.53941/gssd.2026.100019.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.